卵巢早衰的治疗新进展

摘要/Abstract

摘要： 卵巢早衰（POF）是指妇女在40岁之前即发生卵巢功能减退或者衰竭，临床上出现月经紊乱、潮热盗汗、阴道干燥等一系列雌激素低下症状，骨质疏松、神经系统疾病、心血管疾病等风险也增加，影响患者生活质量，此外有可能导致有生育要求的患者不能生育。截至目前，POF发病原因不明，可能与遗传因素、自身免疫因素、代谢因素、环境因素、医源性因素有关。目前激素替代治疗仍是POF的主要治疗方式，虽然可以改善患者临床表现，但无法恢复正常的卵巢功能，也无法达到患者的生育要求。为了改善这一状况，一些新型治疗方法正在发展并且取得了一定进展，如间充质干细胞（MSCs）治疗、富血小板血浆卵巢内输注、卵巢组织的体外激活、外泌体及miRNA治疗。本研究就目前卵巢早衰的治疗进展及其机制进行综述，以期为临床治疗POF提供借鉴和参考。

关键词: font-size:medium, ">卵巢早衰；治疗进展；治疗机制

Abstract: Premature ovarian failure (POF) patients have ovarian dysfunction or even failure before the age of 40， and a series of low estrogen symptoms such as menstrual disorders， hot flashes and night sweats， vaginal dryness and so on appear clinically. The risk of osteoporosis， nervous system disease， cardiovascular disease and other diseases also increased， affecting the quality of life of the patients. In additon， it leads to patients with fertility requirements infertile. The etiology of most POF is unknown， which may be related to genetic factors， autoimmune factors， metabolic factors， environmental factors and iatrogenic factors. At present， hormone replacement therapy is still the main treatment method for POF， which can improve the clinical symptoms of patients， but can not restore the ovarian function and meet the fertility requirements of patients. In order to improve this situation， some new treatment methods are being developed and have made some progress， such as mesenchymal stem cell therapy， platelet-rich plasma intraovarian infusion， ovarian tissue activation in vitro， exosomes and miRNA therapy. This article reviews the current progress in the treatment of premature ovarian failure and its mechanism， so as to provide reference for clinical treatment of POF.

Key words: font-size:medium, ">Premature ovarian failure； Treatment progress； Therapeutic mechanism

中图分类号:

周倩, 卢永超. 卵巢早衰的治疗新进展[J]. 中国医药导刊, 2023, 25(1): 35-38.

ZHOU Qian, LU Yongchao. New Progress in the Treatment of Premature Ovarian Failure[J]. CHINESE JOURNAL OF MEDICINAL GUIDE, 2023, 25(1): 35-38.

参考文献

[1]Patore LM， Christianson MS， Stelling J， et al. Reproductive ovarian testing and the alphabet soup of diagnoses： DOR， POI， POF， POR， and FOR [J]. Journal of Assisted Reproduction and Genetics， 2018， 35(1)： 17-23.
     [2]Zhao H， Shan Y， Ma Z， et al. A network pharmacology approach to explore active compounds and pharmacological mechanisms of epimedium for treatment of premature ovarian insufficiency [J]. Drug Design， Development and Therapy， 2019， 13： 2997-3007.
     [3]Wesevich V， Kellen AN， Pal L. Recent advances in understanding primary ovarian insufficiency [J]. F1000Research， 2020， 9：PMID：32934798.
     [4]Chon S J， Umair Z， Yoon MS. Premature ovarian insufficiency： past， present， and future [J]. Frontiers in Cell and Developmental Biology， 2021， 9： 672890.
     [5]Grossmann B， Saur S， Rall K， et al. Prevalence of autoimmune disease in women with premature ovarian failure [J]. The European Journal of Contraception &Reproductive Health Care ： the Official Journal of the European Society of Contraception， 2020， 25(1)： 72-75.
     [6]Zhang S， Zhu D， Mei X， et al. Advances in biomaterials and regenerative medicine for primary ovarian insufficiency therapy [J]. Bioactive Materials， 2021， 6(7)： 1957-1972.
     [7]张帅，李梅. 早发性卵巢功能不全患者生育力保存研究进展[J].现代妇产科进展，2022， 31(5)： 380-383.
     [8]Ovarian tissue cryopreservation： a committee opinion [J]. Fertility and Sterility， 2014， 101(5)： 1237-1243.
     [9]胥风华，侯亚宁，葛鹏玲，等. 卵巢早衰中医治疗特色[J].辽宁中医药大学学报，2020， 22(1)： 25-28.
     [10]Fu YX， Ji J， Shan F， et al. Human mesenchymal stem cell treatment of premature ovarian failure： new challenges and opportunities [J]. Stem Cell Research &Therapy， 2021， 12(1)： 161.
     [11]Maqsood M， Kang M， Wu X， et al. Adult mesenchymal stem cells and their exosomes： sources， characteristics， and application in regenerative medicine [J]. Life Sciences， 2020， 256： 118002.
     [12]Lv X， Guan C， Li Y， et al. Effects of single and multiple transplantations of human umbilical cord mesenchymal stem cells on the recovery of ovarian function in the treatment of premature ovarian failure in mice [J]. Journal of Ovarian Research， 2021， 14(1)： 119.
     [13]Li Z， Zhang M， Tian Y， et al. Mesenchymal stem cells in premature ovarian insufficiency： mechanisms and prospects[J]. Frontiers in Cell and Developmental Biology， 2021， 9： 718192.
     [14]Salvatore G， De Felici M， Dolci S， et al. Human adipose-derived stromal cells transplantation prolongs reproductive lifespan on mouse models of mild and severe premature ovarian insufficiency[J]. Stem Cell Research & Therapy， 2021， 12(1)： 537.
     [15]Ling L， Feng X， Wei T， et al. Human amnion-derived mesenchymal stem cell (hAD-MSC) transplantation improves ovarian function in rats with premature ovarian insufficiency (POI) at least partly through a paracrine mechanism [J]. Stem Cell Research & Therapy， 2019， 10(1)： 46.
     [16]Yin N， Zhao W， Luo Q， et al. Restoring ovarian function with human placenta-derived mesenchymal stem cells in autoimmune-induced premature ovarian failure mice mediated by treg cells and associated cytokines[J]. Reproductive Sciences (Thousand Oaks， Calif)， 2018， 25(7)： 1073-1082.
     [17]Bao R， Xu P， Wang Y， et al. Bone marrow derived mesenchymal stem cells transplantation rescues premature ovarian insufficiency induced by chemotherapy [J]. Gynecological Endocrinology： the Official Journal of the International Society of Gynecological Endocrinology， 2018， 34(4)： 320-326.
     [18]Cui L， Bao H， Liu Z， et al. hUMSCs regulate the differentiation of ovarian stromal cells via TGF-β(1)/Smad3 signaling pathway to inhibit ovarian fibrosis to repair ovarian function in POI rats [J]. Stem Cell Research & Therapy， 2020， 11(1)： 386.
     [19]Dhurat R， Sukesh M. Principles and methods of preparation of platelet-rich plasma： a review and author′s perspective [J]. Journal of Cutaneous and Aesthetic Surgery， 2014， 7(4)： 189-197.
     [20]Dos Santos RG， Santos GS， Alkass N， et al. The regenerative mechanisms of platelet-rich plasma： a review [J]. Cytokine， 2021， 144： 155560.
     [21]Chang Y， Li J， Wei LN， et al. Autologous platelet-rich plasma infusion improves clinical pregnancy rate in frozen embryo transfer cycles for women with thin endometrium [J]. Medicine， 2019， 98(3)： e14062.
     [22]Sfakianoudis K， Simopoulou M， Grigoriadis S， et al. Reactivating ovarian function through autologous platelet-rich plasma intraovarian infusion： pilot data on premature ovarian insufficiency， perimenopausal， menopausal， and poor responder women[J]. J Clinical Medicine， 2020， 9(6)：1809.
     [23]Cakiroglu Y， Saltik A， Yuceturk A， et al. Effects of intraovarian injection of autologous platelet rich plasma on ovarian reserve and IVF outcome parameters in women with primary ovarian insufficiency [J]. Aging， 2020， 12(11)： 10211-10222.
     [24]Atkinson L， Martin F， Syurmey RG. Intraovarian injection of platelet-rich plasma in assisted reproduction： too much too soon? [J]. Human Reproduction (Oxford， England)， 2021， 36(7)： 1737-1750.
     [25]De Vos M， Devroey P， Fauser BC. Primary ovarian insufficiency [J]. Lancet (London， England)， 2010， 376(9744)： 911-921.
     [26]Hsueh A J W， Kawamura K. Hippo signaling disruption and ovarian follicle activation in infertile patients [J]. Fertility and Sterility， 2020， 114(3)： 458-464.
     [27]Kawamura K， Cheng Y， Suzuki N， et al. Hippo signaling disruption and Akt stimulation of ovarian follicles for infertility treatment [J]. Proceedings of the National Academy of Sciences of the United States of America， 2013， 110(43)： 17474-17479.
     [28]Wang W， Todorov P， Isachenko E， et al. In vitro activation of cryopreserved ovarian tissue： a single-arm meta-analysis and systematic review [J]. European Journal of Obstetrics， Gynecology， and Reproductive Biology， 2021， 258： 258-264.
     [29]Ferreri J， Fàbregues F， Calafell JM， et al. Drug-free in-vitro activation of follicles and fresh tissue autotransplantation as a therapeutic option in patients with primary ovarian insufficiency [J]. Reproductive Biomedicine Online， 2020， 40(2)： 254-260.
     [30]Barile L， Vassalli G. Exosomes： therapy delivery tools and biomarkers of diseases [J]. Pharmacology & Therapeutics， 2017， 174： 63-78.
     [31]Tesfaye D， Gebremedhn S， Salilew-wondim D， et al. MicroRNAs： tiny molecules with a significant role in mammalian follicular and oocyte development [J]. Reproduction (Cambridge， England)， 2018， 155(3)： R121-R135.
     [32]Yang M， Lin L， Sha C， et al. Bone marrow mesenchymal stem cell-derived exosomal miR-144-5p improves rat ovarian function after chemotherapy-induced ovarian failure by targeting PTEN [J]. Laboratory Tnvestigation： a J Technical Methods and Pathology， 2020， 100(3)： 342-352.
     [33]Ding C， Zhu L， Shen H， et al. Exosomal miRNA-17-5p derived from human umbilical cord mesenchymal stem cells improves ovarian function in premature ovarian insufficiency by regulating SIRT7 [J]. Stem Cells (Dayton， Ohio)， 2020， 38(9)： 1137-1148.

快速检索引用检索图表检索高级检索